.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The ORIGINAL randomized clinical trial compared tenecteplase with alteplase for acute ischemic stroke treated within 4.5 hours of symptom onset. Tenecteplase was given as a single intravenous bolus, whereas alteplase required an infusion. Among nearly 1,500 randomized patients, the proportion achieving an excellent functional outcome at 90 days was numerically higher with tenecteplase, and the prespecified non-inferiority criterion was met. Symptomatic intracerebral haemorrhage and mortality were similar between groups. The results add substantial evidence supporting tenecteplase as an alternative thrombolytic agent in eligible patients. The single-bolus administration may simplify logistics, which is especially relevant in high-volume stroke pathways and systems where treatment speed matters. For HCPs, the trial should be interpreted within current stroke protocols and eligibility criteria. Tenecteplase does not replace the need for rapid imaging, vascular assessment and mechanical thrombectomy when indicated. Its value is as a practical reperfusion option within the appropriate therapeutic window. The evidence is directly relevant to IANCON's focus on acute ischemic stroke, thrombolysis and vascular neurology.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The ORIGINAL randomized clinical trial compared tenecteplase with alteplase for acute ischemic stroke treated within 4.5 hours of symptom onset. Tenecteplase was given as a single intravenous bolus, whereas alteplase required an infusion. Among nearly 1,500 randomized patients, the proportion achieving an excellent functional outcome at 90 days was numerically higher with tenecteplase, and the prespecified non-inferiority criterion was met. Symptomatic intracerebral haemorrhage and mortality were similar between groups. The results add substantial evidence supporting tenecteplase as an alternative thrombolytic agent in eligible patients. The single-bolus administration may simplify logistics, which is especially relevant in high-volume stroke pathways and systems where treatment speed matters. For HCPs, the trial should be interpreted within current stroke protocols and eligibility criteria. Tenecteplase does not replace the need for rapid imaging, vascular assessment and mechanical thrombectomy when indicated. Its value is as a practical reperfusion option within the appropriate therapeutic window. The evidence is directly relevant to IANCON's focus on acute ischemic stroke, thrombolysis and vascular neurology.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
2 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
3 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
3 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
3 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
3 days back
